Loading...
XKRX
003060
Market cap96mUSD
Jul 11, Last price  
673.00KRW
1D
2.91%
1Q
-2.89%
Jan 2017
-96.62%
Name

Aprogen Biologics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
1.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-11.27%
Rev. gr., 5y
5.77%
Revenues
67.38b
-22.88%
17,117,086,00021,137,045,00062,227,816,00016,689,083,00050,122,955,34033,769,678,25029,543,262,23033,092,222,03040,324,275,48044,122,492,68046,100,951,70045,395,389,40050,903,820,55053,319,976,20056,481,701,59065,190,359,33087,363,627,71267,378,141,310
Net income
-104.98b
L-11.24%
-10,496,595,000-5,489,801,000-8,097,501,000-704,422,000-4,560,115,000-24,870,962,000-20,852,021,000-3,887,364,7402,760,674,900-3,917,714,760-16,364,749,000-1,215,412,540-3,466,524,12018,917,569,9608,102,570,3705,583,620,100-118,269,720,510-104,978,891,930
CFO
-31.00b
L-7.89%
-4,773,709,000-3,461,909,000-4,994,895,000247,922,000-3,895,277,730-1,649,487,870-1,701,829,640-6,917,181,5701,847,053,050449,980,360-8,927,787,2801,331,380,770713,734,0208,088,157,750-6,226,540,19025,728,188,300-33,650,775,380-30,996,492,830
Earnings
Aug 12, 2025

Profile

Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. The company was formerly known as Schnell Biopharmaceuticals, Inc. and changed its name to Aprogen pharmaceuticals,Inc. in April 2017. Aprogen pharmaceuticals,Inc. was founded in 1960 and is headquartered in Seongnam, South Korea.
URL
http://www.aprogen-pharm.com/
IPO date
Oct 19, 1984
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
67,378,141
-22.88%
87,363,628
34.01%
65,190,359
15.42%
Cost of revenue
109,733,664
132,962,765
57,926,980
Unusual Expense (Income)
NOPBT
(42,355,523)
(45,599,137)
7,263,379
NOPBT Margin
11.14%
Operating Taxes
1,947,066
1,260,151
Tax Rate
17.35%
NOPAT
(42,355,523)
(47,546,203)
6,003,228
Net income
(104,978,892)
-11.24%
(118,269,721)
-2,218.15%
5,583,620
-31.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
115,736,890
35,574,520
244
BB yield
-19.39%
0.00%
Debt
Debt current
105,820,538
130,720,460
134,608,901
Long-term debt
66,584,014
69,913,837
603,620
Deferred revenue
Other long-term liabilities
12,714,899
9,558,467
9,386,470
Net debt
68,104,530
52,934,337
53,810,668
Cash flow
Cash from operating activities
(30,996,493)
(33,650,775)
25,728,188
CAPEX
(15,264,437)
(28,087,917)
(1,545,199)
Cash from investing activities
(51,722,492)
(95,205,708)
(53,000,826)
Cash from financing activities
84,971,794
115,289,354
15,782,353
FCF
(33,066,639)
25,056,526
(192,499,302)
Balance
Cash
38,318,700
10,053,360
99,073,617
Long term investments
65,981,322
137,646,600
(17,671,765)
Excess cash
100,931,114
143,331,779
78,142,334
Stockholders' equity
(139,795,610)
(180,413,847)
366,504,224
Invested Capital
685,018,962
739,661,086
568,351,578
ROIC
1.13%
ROCE
1.12%
EV
Common stock shares outstanding
83,225
53,652
Price
662.00
-69.96%
2,203.96
-42.35%
3,822.73
-44.42%
Market cap
183,424,057
-10.57%
205,096,227
-44.06%
EV
236,358,395
339,561,644
EBITDA
(23,265,263)
(24,201,534)
9,667,364
EV/EBITDA
35.12
Interest
5,514,015
3,668,234
274,408
Interest/NOPBT
3.78%